A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

NCT06732323 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

504

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple-Negative Breast Cancer (TNBC)

Interventions

DRUG: ESG401
DRUG: Investigator's Choice Chemotherapy

Sponsor

Qilu Pharmaceutical Co., Ltd.